A review on atrioventricular junction ablation and pacing for heart rate control of atrial fibrillation

Journal of Geriatric Cardiology

Volumn 12, Issue 5, 2015, Pages 547-554

  Vlachos, Konstantinos ^a   Letsas, Konstantinos P ^a   Korantzopoulos, Panagiotis ^b   Liu, Tong ^c   Efremidis, Michael ^a   Sideris, Antonios ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^c SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Ablation; Atrial fibrillation; Atrioventricular junction; Pacemaker

Indexed keywords

ATRIAL FIBRILLATION; CARDIAC PATIENT; CATHETER ABLATION; CLINICAL EFFECTIVENESS; DEVICE THERAPY; HEART ATRIOVENTRICULAR NODE; HEART PACING; HEART RATE; HUMAN; LONG TERM SURVIVAL; MEDICAL TECHNOLOGY; PACEMAKER; PACEMAKER IMPLANTATION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84944038405     PISSN: 16715411     EISSN: None     Source Type: Journal    
DOI: 10.11909/j.issn.1671-5411.2015.05.005     Document Type: Review

References (62)

1. Braunwald E. Shattuck lecture: cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997; 337: 1360-1369.
2. Efremidis M, Letsas KP, Lioni L, et al. Association of quality of life, anxiety, and depression with left atrial ablation outcomes. Pacing Clin Electrophysiol 2014; 37: 703-711.
3. Deedwania PC, Lardizabal JA. Atrial fibrillation in heart failure: a comprehensive review. Am J Med 2010; 123: 198-204.
4. Corday E, Gold H, de Vera LB, et al. Effect of the cardiac arrhythmias on the coronary circulation. Ann Intern Med 1959; 50: 535-553.
5. Coleman HN, Taylor RR, Pool PE, et al. Congestive heart failure following chronic tachycardia. Am Heart J 1971; 81: 790-798.
6. Riegger AJG, Liebau G. The renin-angiotensin-aldosterone system, antidiuretic hormone and sympathetic nerve activity in an experimental model of congestive heart failure in the dog. Clin Sci 1982; 62: 465-469.
7. Armstrong PW, Stopps TP, Ford SE, et al. Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. Circulation 1986; 74: 1075-1084.
8. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-1840.
9. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
10. Wood MA, Brown-Mahoney C, Kay GN, et al. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: A meta-analysis. Circulation 2000; 101: 1138-1144.
11. Chatterjee NA, Upadhyay GA, Ellenbogen KA, et al. Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis and systematic review. Circ Arrhythm Electrophysiol 2012; 5: 68-76.
12. Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011; 57: e101-e198.
13. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64: e1-e76.
14. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
15. Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J 2013; 34: 2281-2329.
16. Scheinman MM, Huang S. The 1998 NASPE prospective catheter ablation registry. Pacing Clin Electrophysiol 2000; 23: 1020-1028.
17. Curtis AB, Kutalek SP, Prior M, et al. Prevalence and characteristics of escape rhythms after radiofrequency ablation of the atrioventricular junction: results from the registry for AV junction ablation and pacing in atrial fibrillation. Am Heart J 2000; 139: 122-125.
18. Sousa J, El-Atassi R, Rosenheck S, et al. Radiofrequency catheter ablation of the atrioventricular junction from the left ventricle. Circulation 1991; 84: 567-571.
19. Marshall HJ, Griffith MJ. Ablation of the atrioventricular junction: Technique, acute and long-term results in 115 consecutive patients. Europace 1999; 1: 26-29.
20. Souza O, Gürsoy S, Simonis F, et al. Right-sided versus left-sided radiofrequency ablation of the His bundle. Pacing Clin Electrophysiol 1992; 15: 1454-1459.
21. Darpö B, Walfridsson H, Aunes M, et al. Incidence of sudden death after radiofrequency ablation of the atrioventricular junction for atrial fibrillation. Am J Cardiol 1997; 80: 1174-1177.
22. Ozcan C, Jahangir A, Friedman PA, et al. Sudden death after radiofrequency ablation of the atrioventricular node in patients with atrial fibrillation. J Am Coll Cardiol 2002; 40: 105-110.
23. Sadoul N, Blankoff I, de Chillou C, et al. Effects of radiofrequency catheter ablation on patients with permanent pacemakers. J Interv Card Electrophysiol 1997; 1: 227-233.
24. Geelen P, Brugada J, Andries E, et al. Ventricular fibrillation and sudden death after radiofrequency catheter ablation of the atrioventricular junction. Pacing Clin Electrophysiol 1997; 20: 343-348.
25. Schumacher B, Pfeiffer D, Tebbenjohanns J, et al. Acute and long-term effects of consecutive radiofrequency applications on conduction properties of the subeustachian isthmus in type I atrial flutter. J Cardiovasc Electrophysiol 1998; 9: 152-163.
26. Blanck Z, Dhala AA, Sra J, et al. Characterization of atrioventricular nodal behavior and ventricular response during atrial fibrillation before and after a selective slow-pathway ablation. Circulation 1995; 91: 1086-1094.
27. Della Bella P, Carbucicchio C, Tondo C, et al. Modulation of atrioventricular conduction by ablation of the "slow" atrioven-tricular node pathway in patients with drug-refractory atrial fibrillation or flutter. J Am Coll Cardiol 1995; 25: 39-46.
28. Menozzi C, Brignole M, Gianfranchi L, et al. Radiofrequency catheter ablation and modulation of atrioventricular conduction in patients with atrial fibrillation. Pacing Clin Electrophysiol 1994; 17: 2143-2149.
29. Feld GK. Radiofrequency catheter ablation versus modification of the AV node for control of rapid ventricular response in atrial fibrillation. J Cardiovasc Electrophysiol 1995; 6: 217-228.
30. Canby RC, Román CA, Kessler DJ, et al. Selective radiofrequency ablation of the "slow" atrioventricular nodal pathway for control of the ventricular response to atrial fibrillation. Am J Cardiol 1996; 77: 1358-1361.
31. Fleck RP, Chen PS, Boyce K, et al. Radiofrequency modification of atrioventricular conduction by selective ablation of the low posterior septal right atrium in a patient with atrial fibrillation and a rapid ventricular response. Pacing Clin Electrophysiol 1993; 16: 377-381.
32. Proclemer A, Della Bella P, Tondo C, et al. Radiofrequency ablation of atrioventricular junction and pacemaker implantation versus modulation of atrioventricular conduction in drug refractory atrial fibrillation. Am J Cardiol 1999; 83: 1437-1442.
33. Lee SH, Chen SA, Tai CT, et al. Comparisons of quality of life and cardiac performance after complete atrioventricular junction ablation and atrioventricular junction modification in patients with medically refractory atrial fibrillation. J Am Coll Cardiol 1998; 31: 637-644.
34. Bongiorni MG, Proclemer A, Dobreanu D, et al. Preferred tools and techniques for implantation of cardiac electronic devices in Europe: results of the European Heart Rhythm Association survey. Europace 2013; 15: 1664-1668.
35. Proclemer A, Facchin D, Pagnutti C, et al. Safety of pacemaker implantation prior to radiofrequency ablation of atrioventricular junction in a single session procedure. Pacing Clin Electrophysiol 2000; 23: 998-1002.
36. Kay GN, Bubien RS, Epstein AE, et al. Effect of catheter ablation of the atrioventricular junction on quality of life and exercise tolerance in paroxysmal atrial fibrillation. Am J Cardiol 1988; 62: 741-744.
37. Brignole M, Gianfranchi L, Menozzi C, et al. Influence of atrioventricularjunction radiofrequency ablation in patients with chronic atrial fibrillation and flutter on quality of life and cardiac performance. Am J Cardiol 1994; 74: 242-246.
38. Fitzpatrick AP, Kourouyan HD, Siw A, et al. Quality of life and outcomes after radiofrequency His-bundle catheter ablation and permanent pacemaker implantation: impact of treatment in paroxysmal and established atrial fibrillation. Am Heart J 1996; 131: 499-507.
39. Kay GN, Ellenbogen KA, Giudici M, et al. The Ablate and Pace Trial: A prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. J Interv Card Electrophysiol 1998; 2: 121-135.
40. Bedotto JB, Grayburn PA, Black WH, et al. Alterations in left ventricular relaxation during atrioventricular pacing in humans. J Am Coll Cardiol 1990; 15: 658-664.
41. Karpawich PP, Rabah R, Haas JE. Altered cardiac histology following apical right ventricular pacing in patients with congenital atrioventricular block. Pacing Clin Electrophysiol 1999; 22: 1372-1377.
42. Wilkoff BL, Cook JR, Epstein AE, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 2002; 288: 3115-3123.
43. Barsheshet A, Moss AJ, McNitt S, et al. Long-term implications of cumulative right ventricular pacing among patients with an implantable cardioverter-defibrillator. Heart Rhythm 2011; 8: 212-218.
44. Chen L, Hodge D, Jahangir A, et al. Preserved left ventricular ejection fraction following atrioventricular junction ablation and pacing for atrial fibrillation. J Cardiovasc Electrophysiol 2008; 19: 19-27.
45. Abraham WT, Fisher WG, Smith AL, et al; MIRACLE Study Group. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845-1853.
46. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-2150.
47. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344: 873-880.
48. Gras D, Leclercq C, Tang AS, et al. Cardiac resynchronization therapy in advanced heart failure the multicenter InSync clinical study. Eur J Heart Fail 2002; 4: 311-320.
49. Higgins SL, Hummel JD, Niazi IK, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 2003; 42: 1454-1459.
50. Linde C, Leclercq C, Rex S, et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 2002; 40: 111-118.
51. Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 2003; 289: 2685-2694.
52. Doshi RN, Daoud EG, Fellows C, et al; PAVE Study Group. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol 2005; 16: 1160-1165.
53. Molhoek SG, Bax JJ, Bleeker GB, et al. Comparison of response to cardiac resynchronization therapy in patients with sinus rhythm versus chronic atrial fibrillation. Am J Cardiol 2004; 94: 1506-1509.
54. Gasparini M, Auricchio A, Regoli F, et al. Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation. J Am Coll Cardiol 2006; 48: 734-743.
55. Tolosana JM, Hernandez Madrid A, Brugada J, et al. Comparison of benefits and mortality in cardiac resynchronization therapy in patients with atrial fibrillation versus patients in sinus rhythm (Results of the Spanish Atrial Fibrillation and Resynchronization [SPARE] Study). Am J Cardiol 2008; 102: 444-449.
56. Gasparini M, Auricchio A, Metra M, et al. Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J 2008; 29: 1644-1652.
57. Ferreira AM, Adragao P, Cavaco DM, et al. Benefit of cardiac resynchronization therapy in atrial fibrillation patients vs. patients in sinus rhythm: the role of atrioventricular junction ablation. Europace 2008; 10: 809-815.
58. Dong K, Shen WK, Powell BD, et al. Atrioventricular nodal ablation predicts survival benefit in patients with atrial fibrillation receiving cardiac resynchronization therapy. Heart Rhythm 2010; 7: 1240-1245.
59. Delnoy PP, Ottervanger JP, Luttikhuis HO, et al. Comparison of usefulness of cardiac resynchronization therapy in patients with atrial fibrillation and heart failure versus patients with sinus rhythm and heart failure. Am J Cardiol 2007; 99: 1252-1257.
60. Khadjooi K, Foley PW, Chalil S, et al. Long-term effects of cardiac resynchronization therapy in patients with atrial fibrillation. Heart 2008; 94: 879-883.
61. Schutte F, Ludorff G, Grove R, et al. Atrioventricular node ablation is not a prerequisite for cardiac resynchronization therapy in patients with chronic atrial fibrillation. Cardiology 2009; 16: 246-249.
62. Reddy VY, Knops RE, Sperzel J, et al. Permanent leadless cardiac pacing: results of the leadless trial. Circulation 2014; 129: 1466-1471.